𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The value of adriamycin in the treatment of diffuse malignant pleural mesothelioma

✍ Scribed by Boh-Seng Yap; Robert S. Benjamin; M. Andrew Burgess; Gerald P. Bodey

Publisher
John Wiley and Sons
Year
1978
Tongue
English
Weight
391 KB
Volume
42
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Intrapleural administration of interleuk
Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma : A Phase II study
✍ Philippe Astoul; Diane Picat-Joossen; Jean-Regis Viallat; Christian Boutin πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 82 KB πŸ‘ 2 views

## Background: The prognosis associated with malignant pleural mesothelioma (mpm) is poor in spite of surgery, radiotherapy, photodynamic therapy, or chemotherapy. therefore, new therapeutic strategies, including intrapleural immunotherapy, are being investigated. several clinical studies have demo

Intrapleural administration of interleuk
Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma : A Phase II study
✍ Theodore G. Karrison; Nicholas J. Vogelzang πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 52 KB πŸ‘ 2 views

## Stage I Renal Cell Carcinoma I read the report by Kinouchi et al., 1 in which they concluded that the tumor grading of renal cell carcinoma was not predictive of the survival of Robson Stage I patients. This does not mean that the three-grading system is worthless; the authors simply showed tha

Quinacrine in the management of malignan
Quinacrine in the management of malignant pleural effusion
✍ S. A. Taylor; N. S. Hooton; A. M. Macarthur πŸ“‚ Article πŸ“… 1977 πŸ› John Wiley and Sons 🌐 English βš– 209 KB πŸ‘ 2 views

## Abstract Twenty-five patients with malignant pleural effusion were treated with a single intrapleural dose of Quinacrine. Eighteen patients (72 per cent) had a significant response, with no reaccumulation of fluid for at least 2 months following treatment up to a maximum of 18 months in 2 patien

A phase II study of gemcitabine in patie
A phase II study of gemcitabine in patients with malignant pleural mesothelioma
✍ Jan P. van Meerbeeck; Paul Baas; Channa Debruyne; Harry J. Groen; Chris Manegold πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 115 KB πŸ‘ 2 views

## BACKGROUND. Gemcitabine has shown activity in patients with less chemosensitive solid tumors. Phase II screening of novel drugs is an accepted method with which to investigate new therapies in malignant mesothelioma. The European Organization for Research and Treatment of Cancer-Lung Cancer Coo